.
.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv)..
.
despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6..
'indian ip and liabilities law barrier to pharma r&d investment'
.
fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and